 |
|
|
|
 |
|
|
| Article 1 to 10 out of 17 concerning Boehringer Ingelheim Pharma GmbH & Co. KG
|
-
Boehringer Ingelheim licenses drug targets from autoimmune collaboration with Galapagos
(07/18/2008)
Galapagos NV announced that Boehringer Ingelheim has exercised its right to license two drug targets from the autoimmune research agreement with Galapagos' BioFocus DPI service division, resulting in a milestone payment to Galapagos.This is the ...
-
Boehringer Ingelheim completes $36 million investment in Laval for state-of-the-art research centre
(05/28/2008)
New facility dedicated to finding treatments for serious infectious diseases
Boehringer Ingelheim completed a $36 million investment in new laboratories in Laval, Quebec, designed to support research into treatments for serious infectious diseases. The new facility will allow Boehringer Ingelheim to hire 40 additional ...
-
ProBioGen and Boehringer Ingelheim enter into Strategic Production Alliance
(05/02/2008)
ProBioGen AG announced a strategic production agreement with Boehringer Ingelheim. Under the agreement, ProBioGen will integrate some of Boehringer Ingelheimīs technologies to accommodate a seamless process and technology transfer from pilot and ...
-
Data suggests promising overall survival and progression-free survival with VARGATEF (BIBF 1120)
(04/29/2008)
Latest phase II data for Boehringer Ingelheim's new cancer drug in development
Monotherapy treatment with the triple angiokinase inhibitor BIBF 1120 (planned tradename VARGATEF(TM)) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small cell lung cancer (NSCLC), according to results from ...
-
BIOMEVA and Boehringer Ingelheim strengthen their biomanufacturing services in a production alliance
(11/19/2007)
BIOMEVA GmbH and Boehringer Ingelheim announced that both companies have entered into a production alliance agreement. With this collaboration BIOMEVA GmbH may have non-exclusive access to Boehringer Ingelheim's comprehensive manufacturing ...
-
Boehringer Ingelheim Offers a Licence to Apotex to Export BI's patented product nevirapine to Developing Countries
(08/27/2007)
Boehringer Ingelheim has offered the Canadian generic pharmaceutical manufacturer Apotex Inc. a royalty free, voluntary licence to manufacture and export products containing nevirapine to Rwanda as requested by Apotex. Boehringer Ingelheim has also ...
-
Dalton Medicinal Chemistry Partners and Boehringer Ingelheim (Canada) Ltd. enter into a Medicinal Chemistry Agreement
(03/27/2007)
Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announced the signing of a Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.Dalton Medicinal Chemistry Partners will utilize their ...
-
Laureate Pharma announces collaboration with Boehringer Ingelheim
(02/08/2007)
Laureate Pharma, Inc. announced a preferred partnership agreement with Boehringer Ingelheim. With this collaboration, Laureate's clients will gain access to Boehringer Ingelheim's comprehensive manufacturing technology platform for biopharmaceutical ...
-
Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim
(04/06/2006)
Digilab BioVisioN GmbH announced closing of a cooperation contract with Boehringer Ingelheim Pharma GmbH & Co. KG. This is the first collaboration contract of the company that takes over commercial activities from BioVisioN AG within a ...
-
Boehringer Ingelheim and Biolipox sign agreement on a new class of drugs to treat pain and inflammation
(11/15/2005)
Boehringer Ingelheim GmbH and Biolipox announced today that they agreed to a worldwide exclusive research and license collaboration. The aim of the collaboration is to develop a new class of drugs with a novel mechanism of action for the treatment ...
|
|
|
|
|
Top